Interview with Dr. Lou Vaickus, Tolerx, Question 6

DJ: Will there be any application of this drug class for Type 2 diabetes?

LV: Fascinating question!  There have been very early studies to suggest that  many of the problems that Type 2 diabetes patients have (increased heart disease and insulin resistance as examples) have their origin in an immune response in abdominal visceral adipose tissue that promotes inflammation and hence, damage to many organs. In one study in mice, an anti-CD3 antibody, given as a single treatment course for a short period of time (just like in Type 1 patients with otelixizumab), resulted in durable effects on insulin resistance. So, the answer here is … stay tuned.